FCA
RANI icon

FinTrust Capital Advisors’s Rani Therapeutics RANI Stock Holding History

FinTrust Capital Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-75
Closed -$443 – 1326
2023
Q2 		$443 Hold
75
– – ﹤0.01% 1148
2023
Q1 		$443 Hold
75
– – ﹤0.01% 1139
2022
Q4 		$442 Buy
+75
New +$547 ﹤0.01% 1136

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASGS
Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

FinTrust Capital Advisors's RANI Position: Q3 2023 in Review

FinTrust Capital Advisors sold out of Rani Therapeutics (RANI) in Q3 2023, closing a stake of 75 shares — an estimated $443 sold.

FinTrust Capital Advisors first reported a position in RANI in Q4 2022 and held it in 3 quarters. The position peaked at $443 in Q2 2023. 34 funds tracked by Wall St. Rank hold RANI as of Q3 2023.

  • FinTrust Capital Advisors reported no remaining Rani Therapeutics position as of Q3 2023 after selling out during the quarter.
  • FinTrust Capital Advisors sold 75 Rani Therapeutics shares in Q3 2023, an estimated $443.
  • FinTrust Capital Advisors first reported a position in Rani Therapeutics in Q4 2022 and held it in 3 quarters.
  • FinTrust Capital Advisors's Rani Therapeutics position peaked at $443 in Q2 2023.
  • 34 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2023.

Based on FinTrust Capital Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.